English	French	Notes	Complete/Exclude
  TYPE OF IMMUNOTHERAPY (BRM):			
TYPE OF FIRST RECURRENCE			
DATE OF FIRST RECURRENCE			
DISTANT SITE(S) OF FIRST RECURRENCE			
TABLE V - FIRST RECURRENCE			
387TYPE OF FIRST RECURRENCE/BLADDER..			
DATE OF FIRST RECURRENCE..........: 			
70DATE OF FIRST RECURRENCE......... 			
DISTANT SITE(S) OF RECURRENCE:			
71.1  RECURRENCE SITE 1...........			
  RECURRENCE SITE 2...........: None			
  RECURRENCE SITE 3...........: None			
71.2  RECURRENCE SITE 2...........			
71.3  RECURRENCE SITE 3...........			
DATE OF LAST CONTACT OR DEATH			
VITAL STATUS			
CANCER STATUS			
REVIEWED BY CANCER COMMITTEE			
TABLE VI - STATUS AT LAST CONTACT			
DATE OF LAST CONTACT OR DEATH.......: 			
15VITAL STATUS........................			
CANCER STATUS.......................: 			
81COMPLETED BY........................			
82REVIEWED BY CANCER COMMITTEE........			
ACCESSION/SEQUENCE NUMBER...........: 			
CLASS OF CASE.......................: 			
PATIENT REFERRED FOR TREATMENT......: 			
ZIP CODE AT DIAGNOSIS...............: 			
BIRTHDATE...........................: 			
RACE................................: 			
SPANISH ORIGIN......................: 			
SEX.................................: 			
PRIMARY PAYER AT DIAGNOSIS..........: 			
LENGTH OF STAY......................: 			
  HEAD AND NECK: 			
SMOKING HISTORY.....................: 			
DURATION OF SMOKING HISTORY.........: 			
DURATION OF SMOKE FREE HISTORY......: 			
TABLE II - DIAGNOSTIC INFORMATION			
  GROSS HEMATURIA...................: 			
  MICROSCOPIC HEMATURIA.............: 			
  URINARY FREQUENCY.................: 			
  BLADDER IRRITIBILITY..............: 			
ONSET OF SYMPTOMS...................: 			
DURATION OF SYMPTOMS:			
  GROSS HEMTURIA....................: 			
  BIMANUAL EXAMINATION OF BLADDER...: 			
  CYSTOSCOPY WITH BIOPSY............: 			
  CYSTOSCOPY WITHOUT BIOPSY.........: 			
  FLOW CYTOMETRY....................: 			
  INTRAVENOUS PYELOGRAM.............: 			
  URINE CYTOLOGY....................: 			
DATE OF INITIAL DIAGNOSIS...........: 			
SPECIALTY MAKING DIAGNOSIS..........: 			
PRIMARY SITE (ICD-O-2)..............: 			
HISTOLOGY (ICD-O-2).................: 			
GRADE...............................: 			
TABLE III - EXTENT OF DISEASE AND AJCC STAGE			
  ABDOMINAL ULTRASOUND: 			
CT OTHER............: 			
  BONE IMAGING........: 			
MRI PELVIS/ABDOMEN..: 			
MRI OTHER...........: 			
  CT CHEST/LUNG.......: 			
OTHER...............: 			
  CT ABDOMEN/PELVIS...: 			
PRESENCE OF HYDRONEPHROSIS..........: 			
TUMOR SIZE (mm).....................: 			
PRESENCE OF MULTIPLE TUMORS.........: 			
REGIONAL NODES EXAMINED.............: 			
REGIONAL NODES POSITIVE.............: 			
SITE(S) OF DISTANT METASTASIS:			
  SITE OF DISTANT METASTASIS #1.....: 			
  SITE OF DISTANT METASTASIS #2.....: 			
  SITE OF DISTANT METASTASIS #3.....: 			
  AJCC STAGE........................: 			
  CLINICAL STAGE....................: 			
  PATHOLOGIC STAGE..................: 			
Print Bladder PCE			
 PCE Study of Cancers of the Urinary Bladder			
PROTOCOL ELIGIBILITY STATUS.........: 			
  PRIMARY PHYSICIAN.................: 			
  SECONDARY PHYSICIAN...............: 			
  TUMOR RESECTION DURING TURB.......: 			
  TYPE OF URINARY DIVERSION.........: 			
  PELVIC LYMPH NODE DISSECTION......: 			
    BLEEDING REQUIRING TRANSFUSION..: 			
    DEEP VENOUS THROMBOSIS..........: 			
    MYOCARDIAL INFARCTION/ARRHYTHMIA: 			
    PELVIC ABSCESS..................: 			
    PNEUMONIA REQUIRING ANTIBIOTICS.: 			
    POST-OPERATIVE DEATH (30 DAYS)..: 			
    PULMONARY EMBOLISM/THROMBOSIS...: 			
  DATE RADIATION THERAPY ENDED......: 			
  TOTAL RAD (cGy/rad) DOSE..........: 			
  REGIONAL TREATMENT MODALITY.......: 			
    URINARY INCONTINENCE............: 			
    RADIATION BOWEL INJURY..........: 			
  DATE CHEMOTHERAPY ENDED...........: 			
  ROUTE CHEMOTHERAPY ADMINISTERED...: 			
IFOSFAMIDE......: 			
METHOTREXATE....: 			
TAXOL...........: 			
THIOTEPA........: 			
VINBLASTINE.....: 			
    GALLIUM NITRATE.: 			
OTHER...........: 			
  INDICATION FOR ADMIN OF AGENTS...: 			
  REASON CHEMOTHERAPY STOPPED......: 			
TYPE OF FIRST RECURRENCE............: 			
DATE OF FIRST RECURRENCE............: 			
DISTANT SITE OF FIRST RECURRENCE 1..: 			
DISTANT SITE OF FIRST RECURRENCE 2..: 			
DISTANT SITE OF FIRST RECURRENCE 3..: 			
DATE OF LAST CONTACT OR DEATH......: 			
VITAL STATUS.......................: 			
CANCER STATUS......................: 			
COMPLETED BY.......................: 			
REVIEWED BY CANCER COMMITTEE.......: 			
The Accession Year is not 1998.			
The Diagnostic Confirmation code is not 1 (Positive histology).			
The Class of Case code is not 1, 2 or 6.			
The Behavior Code is not 2 (In situ) or 3 (Malignant).			
Sex is neither 1 (Male) nor 2 (Female).			
Female patient has neither DCIS nor AJCC tumor size of T1mic or T1a.			
Select Table			
 1998 Patient Care Evaluation Study of Breast Cancer			
1998 Patient Care Evaluation Study of Breast Cancer			
1. INSTITUTION ID NUMBER			
2. ACCESSION NUMBER			
3. SEQUENCE NUMBER			
4. POSTAL CODE AT DIAGNOSIS			
5. DATE OF BIRTH			
7. SPANISH ORIGIN			
9. PRIMARY PAYER AT DIAGNOSIS			
10. FAMILY HISTORY OF BREAST CANCER			
11. (F) PERSONAL HISTORY OF BREAST CANCER			
12. SYNCHRONOUS BREAST CANCER			
13. PERSONAL HISTORY OF OTHER CANCER			
14. (F) HORMONE REPLACEMENT THERAPY			
15. (F) HOW MANY YEARS OF HORMONE REPLACEMENT THERAPY			
 1. INSTITUTION ID NUMBER			
 2. ACCESSION NUMBER			
 3. SEQUENCE NUMBER			
 4. POSTAL CODE AT DIAGNOSIS			
 5. DATE OF BIRTH			
 7. SPANISH ORIGIN			
 9. PRIMARY PAYER AT DIAGNOSIS			
  1. INSTITUTION ID NUMBER..........: H6			
  TABLE I - GENERAL INFORMATION			
  2. ACCESSION NUMBER...............: 			
  3. SEQUENCE NUMBER................: 			
9  4. POSTAL CODE AT DIAGNOSIS.......			
  5. DATE OF BIRTH..................: 			
9  7. SPANISH ORIGIN.................			
18  9. PRIMARY PAYER AT DIAGNOSIS.....			
 10. FAMILY HISTORY OF BREAST CANCER:			
901     MATERNAL AUNT..................			
902     MATERNAL GRANDMOTHER...........			
904     ONE SISTER ONLY................			
905     MORE THAN ONE SISTER...........			
908     POSITIVE FAMILY HISTORY, NOS...			
 11. (F) PERSONAL HISTORY OF BREAST			
     CANCER.........................: (Data Item for Females Only)			
909 11. (F) PERSONAL HISTORY OF BREAST                                                  CANCER.........................			
910 12. SYNCHRONOUS BREAST CANCER......			
 13. PERSONAL HISTORY OF OTHER CANCER:			
     OVARY (F)......................: (Data Item for Females Only)			
     UTERUS (F).....................: (Data Item for Females Only)			
     PROSTATE (M)...................: (Data Item for Males Only)			
 14. (F) HORMONE REPLACEMENT THERAPY: (Data Item for Females Only)			
916 14. (F) HORMONE REPLACEMENT THERAPY			
 15. (F) HOW MANY YEARS OF HORMONE			
     REPLACEMENT THERAPY............: NA			
     REPLACEMENT THERAPY............: Unknown			
     REPLACEMENT THERAPY............: (Data Item for Females Only)			
917 15. (F) HOW MANY YEARS OF HORMONE                                                   REPLACEMENT THERAPY............			
 GO TO ITEM NUMBER: 			
 CHOOSE FROM:			
16. CLASS OF CASE			
17. DIAGNOSTIC EVALUATION			
18. (F) TYPE OF MAMMOGRAM			
19. (F) PRESENTATION OF MOST DEFINITIVE MAMMOGRAM			
20. DATE OF INITIAL DIAGNOSIS			
21. DATE OF PATHOLOGIC DIAGNOSIS			
22. PRIMARY SITE (ICD-O-2)			
24. BEHAVIOR CODE(ICD-O-2)			
25. IF INVASIVE DUCTAL CARCINOMA REPORTED, IS DCIS ALSO PRESENT			
27. ARCHITECTURE PATTERN IF DCIS IS PRESENT			
28. NUCLEAR GRADE IF DCIS IS PRESENT			
29. DIAGNOSTIC CONFIRMATION			
30. (M) LEVEL OF INVOLVEMENT			
31. BIOPSY PROCEDURE			
33. PALPABILITY OF PRIMARY			
34. FIRST DETECTED BY			
24. BEHAVIOR CODE (ICD-O-2)			
 TABLE II - INITIAL DIAGNOSIS			
 16. CLASS OF CASE.................: 			
 17. DIAGNOSTIC EVALUATION:			
     MAMMOGRAM (M).................: (Data Item for Males Only)			
 18. (F) TYPE OF MAMMOGRAM:			
  A. MAMMOGRAM GIVEN, TYPE UNKNOWN.: (Data Item for Females Only)			
  B. SCREENING MAMMOGRAM...........: (Data Item for Females Only)			
  C. DIAGNOSTIC MAMMOGRAM..........: (Data Item for Females Only)			
  D. MAGNIFICATION MAMMOGRAM.......: (Data Item for Females Only)			
918  A. MAMMOGRAM GIVEN, TYPE UNKNOWN.			
920  B. SCREENING MAMMOGRAM...........			
922  C. DIAGNOSTIC MAMMOGRAM..........			
924  D. MAGNIFICATION MAMMOGRAM.......			
 19. (F) PRESENTATION OF MOST			
     DEFINITIVE MAMMOGRAM..........: (Data Item for Females Only)			
928 19. (F) PRESENTATION OF MOST                                                        DEFINITIVE MAMMOGRAM..........			
 20. DATE OF INITIAL DIAGNOSIS.....: 			
929 21. DATE OF PATHOLOGIC DIAGNOSIS..			
 22. PRIMARY SITE (ICD-O-2)........: 			
 24. BEHAVIOR CODE (ICD-O-2).......: 			
 25. IF INVASIVE DUCTAL CARCINOMA			
     REPORTED, IS DCIS ALSO PRESENT: NA, reported tumor not invasive DC			
930 25. IF INVASIVE DUCTAL CARCINOMA                                                    REPORTED, IS DCIS ALSO PRESENT			
931 27. ARCHITECTURE PATTERN IF DCIS                                                    IS PRESENT....................			
932 28. NUCLEAR GRADE IF DCIS IS                                                        PRESENT.......................			
 26. DIAGNOSTIC CONFIRMATION.......: 			
 30. (M) LEVEL OF INVOLVEMENT:			
     SKIN..........................: (Data Item for Males Only)			
     CHEST WALL....................: (Data Item for Males Only)			
     PECTORAL MUSCLES..............: (Data Item for Males Only)			
     DERMAL/LYMPHATIC..............: (Data Item for Males Only)			
934     CHEST WALL....................			
935     PECTORAL MUSCLES..............			
 DIAGNOSTIC AND STAGING PROCEDURES			
141 31. BIOSPY PROCEDURE..............			
 32. GUIDANCE......................: Not guided, no biopsy			
 32. GUIDANCE......................: Unknown/death cert only			
143 33. PALPABILITY OF PRIMARY........			
144 34. FIRST DETECTED BY.............			
35. (M) DNA INDEX/PLOIDY			
36. ESTROGEN RECEPTOR PROTEIN			
37. PROGESTERONE RECEPTOR PROTEIN			
38. (M) ANDROGEN RECEPTOR PROTEIN			
39. TYPE OF TEST			
 TABLE III - TUMOR MARKERS AND PROGNOSTIC TESTS			
 35. (M) DNA INDEX/PLOIDY.........: (Data Item for Males Only)			
937 35. (M) DNA INDEX PLOIDY.........			
 36. ESTROGEN RECEPTOR PROTEIN....: 			
 37. PROGESTERONE RECEPTOR PROTEIN: 			
 38. (M) ANDROGEN RECEPTOR PROTEIN: (Data Item for Males Only)			
940 38. (M) ANDROGEN RECEPTOR PROTEIN			
 39. TYPE OF TEST.................: Neither ERA nor PRA was done			
 39. TYPE OF TEST.................: Unknown if ERA/PRA was done			
941 39. TYPE OF TEST.................			
40. SIZE OF TUMOR (mm)			
41. SIZE OF DCIS TUMOR (mm)			
42. REGIONAL NODES EXAMINED			
43. REGIONAL NODES POSITIVE			
44. SENTINEL NODE BIOSPY			
45. NUMBER OF SENTINEL NODES EXAMINED			
46. NUMBER OF SENTINEL NODES POSITIVE			
47. SENTINEL NODE DETECTED BY			
48. AJCC CLINICAL STAGE (cTNM)			
49. AJCC PATHOLOGIC STAGE (pTNM)			
50. STAGED BY			
 TABLE IV - EXTENT OF DISEASE AND AJCC STAGE			
29 40. SIZE OF TUMOR (mm).......			
 41. SIZE OF DCIS TUMOR (mm)..: NA, reported tumor not invasive DC			
942 41. SIZE OF DCIS TUMOR (mm)..			
33 42. REGIONAL NODES EXAMINED..			
32 43. REGIONAL NODES POSITIVE..			
 SENTINEL NODES			
943 44. SENTINEL NODE BIOPSY.....			
 45. NUMBER OF SENTINEL NODES			
 46. NUMBER OF SENTINEL NODES			
     POSITIVE.................: None examined			
 47. SENTINEL NODE DETECTED BY: NA, not done			
     EXAMINED.................: Unknown if examined			
     POSITIVE.................: Unknown if positive			
 47. SENTINEL NODE DETECTED BY: Method unknown			
944 45. NUMBER OF SENTINEL NODES                                                        EXAMINED.................			
945 46. NUMBER OF SENTINEL NODES                                                        POSITIVE.................			
946 47. SENTINEL NODE DETECTED BY			
 48. AJCC CLINICAL STAGE (cTNM):			
 49. AJCC PATHOLOGIC STAGE (pTNM):			
 50. STAGED BY:			
19     CLINICAL STAGE...........			
89     PATHOLOGIC STAGE.........			
NON CANCER-DIRECTED SURGERY			
CANCER-DIRECTED SURGERY			
HORMONE THERAPY			
 TABLE V - FIRST COURSE OF TREATMENT			
 51. DATE OF FIRST COURSE TREATMENT: 			
 NON CANCER-DIRECTED SURGERY			
 52. DATE OF NON CANCER-DIRECTED			
 53. NON CANCER-DIRECTED SURGERY...: 			
 CANCER-DIRECTED SURGERY			
 54. DATE (FIRST) OF CANCER-			
     DIRECTED SURGERY..............: 			
 55. SURGICAL APPROACH.............: 			
 56. SURGERY OF PRIMARY SITE.......: 			
 57. SPECIMEN RADIOGRAPH...........: NA			
 57. SPECIMEN RADIOGRAPH...........: Unknown			
947 57. SPECIMEN RADIOGRAPH...........			
 58. SURGICAL MARGINS..............: 			
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################